# Supplement

### IL-2, IL-15, and IL-7 Receptor Quantitation

|    Antibody (clone)      	|    Dilution  	|    Fluorophore           	|    Vendor (CAT#)         	|    Panel	| 
|--------------------------	|--------------	|--------------------------	|--------------------------	|----------	|
|    CD25 (M-A251)        	|    1:120   	|    Brilliant   Violet 421	|    BioLegend (356114)    	|    0     	|
|    CD122 (TU27)          	|    1:120     	|    PE/Cy7               	|    BioLegend (339014)    	|    0     	|
|    CD132 (TUGh4)         	|    1:120     	|    APC                 	|    BioLegend (3386       	|    0     	|
|    CD215 1st mAb (JM7A4) 	|    1:120     	|    APC                   	|    BioLegend (330210)    	|    0     	|
|    CD215 2nd mAb (151303)	|    3:100     	|    APC                   	|    R&D Systems (FAB1471A)	|    0     	|
|    CD127 (A019D5)        	|    1:120     	|    Alexa   Fluor 488   	|    BioLegend (351313)    	|    0     	|
|    Ms IgG1κ (MOPC-21) 	|    1:240    	|    Brilliant   Violet 421	|    BioLegend (400158)    	|    0     	|
|    Md IgG1κ (MOPC-21) 	|    1:240    	|    PE/Cy7                	|    BioLegend (400126)    	|    0     	|
|    Rat IgG2Bκ (RTK4530)	|    1:60     	|    APC                   	|    BioLegend (400612)    	|    0     	|
|    Ms IgG2Bκ (MPC-11) 	|    1:120     	|    APC                	|    BioLegend (400320)    	|    0     	|
|    Ms IgG2B (133303)  	|    3:100     	|    APC                	|    R&D Systems (IC0041A) 	|    0     	|
|    Ms IgG1κ  (MOPC-21)	|    1:120     	|    Alexa   Fluor 488     	|    BioLegend (400129)    	|    0     	|
|    CD3 (UCHT1)           	|    1:120     	|    Brilliant   Violet 605	|    BioLegend (300460)    	|    1     	|
|    CD4 (RPA-T4)          	|    1:120     	|    Brilliant   Violet 785	|    BioLegend (300554)    	|    1     	|
|    CD127 (A019D5)       	|    1:120     	|    Alexa Fluor   488     	|    BioLegend (351313)    	|    1     	|
|    CD45RA (HI100)        	|    1:120     	|    PE/Dazzle   594      	|    BioLegend (304146)    	|    1     	|
|    CD3 (UCHT1)          	|    1:120     	|    Brilliant   Violet 605	|    BioLegend (300460)    	|    2     	|
|    CD56 (5.1H11)      	|    1:120     	|    PE/Dazzle   594       	|    BioLegend (362544)    	|    2     	|
|    CD3 (UCHT1)           	|    1:120     	|    Brilliant   Violet 605	|    BioLegend (300460)    	|    3     	|
|    CD8 (RPA-T8)          	|    1:120     	|    Brilliant   Violet 785	|    BioLegend (301046)    	|    3     	|
|    CD45RA (HI100)        	|    1:120     	|    PE/Dazzle   594      	|    BioLegend (304146)    	|    3     	|
|    CD25 (M-A251)         	|    1:120     	|    Brilliant   Violet 421	|    BioLegend (356114)    	|    4     	|
|    CD3 (UCHT1)           	|    1:120     	|    Brilliant   Violet 605	|    BioLegend (300460)    	|    4     	|
|    CD4 (RPA-T4)         	|    1:120     	|    Brilliant   Violet 785	|    BioLegend (300554)    	|    4     	|
|    CD127 (A019D5)       	|    1:120     	|    Alexa Fluor    488   	|    BioLegend (351313)    	|    4     	|
|    CD45RA (HI100)        	|    1:120     	|    PE/Dazzle   594       	|    BioLegend (304146)    	|    4     	|
|    CD56 (5.1H11)        	|    1:120     	|    PE/Cy7                	|    BioLegend (362510)    	|    4     	|
|    CD8 (RPA-T8)          	|    1:120     	|    Alexa Fluor    647    	|    BioLegend (301062)    	|    4     	|
|    Foxp3 (259D)          	|    1:50     	|    Alexa Fluor    488   	|    BioLegend (320212)    	|    5     	|
|    CD25 (M-A251)         	|    1:120     	|    Brilliant   Violet 421	|    BioLegend (356114)    	|    5     	|
|    CD4 (SK3)             	|    1:120     	|    Brilliant   Violet 605	|    BioLegend (344646)    	|    5     	|
|    CD45RA (HI100)        	|    1:120     	|    PE/Dazzle   594      	|    BioLegend (304146)    	|    5     	|
|    pSTAT5 (C71E5)        	|    1:120     	|    Alexa Fluor    647    	|    $\mathrm{CST^{*}}$ (9365)            	|    5     	|
|    CD3 (UCHT1)           	|    1:120     	|    Brilliant   Violet 605	|    BioLegend (300460)    	|    6     	|
|    CD8 (RPA-T8)          	|    1:120     	|    Alexa Fluor    647   	|    BioLegend (301062)    	|    6     	|
|    CD56 (5.1H11)         	|    1:120     	|    Alexa Fluor    488    	|    BioLegend (362518)    	|    6     	|
|    pSTAT5 (D4737)        	|    1:120     	|    PE                  	|    $\mathrm{CST^{*}}$ (14603)           	|    6     	|

: **Antibodies used to quantify receptors and cell types.** *Panel 0:* Antibodies for IL-2, IL-15, and IL-7 receptor analysis; *Panel 1:* Antibodies to gate Naïve and Memory T-regulatory and T-helper cells; *Panel 2:* Antibodies to gate NK and CD56bright NK cells; *Panel 3:* Antibodies to gate Naïve and Memory Cytotoxic T cells; *Panel 4:* Antibodies to gate Naïve and Memory T-regulatory, T helper, and Cytotoxic cells, and NK cells for CD127 (IL-7) Quantitation; *Panel 5:* Antibodies to gate Memory and Naïve T-regulatory cells, Memory and Naïve T-helper cells; *Panel 6:* Antibodies to gate NK cells, CD56bright NK cells, and Cytotoxic T cells. $\mathrm{^{*}}$CST: Cell Signaling Technology.

\cleardoublepage

### IL-2 variants' mutations and conjugations

|    Ligand      	|    Fc Conjugation  	|    Specificity Mutation           	|    Other Mutations         	| 
|--------------------------	|--------------	|--------------------------	|--------------------------	|
|    F42Q N-Term        	|    N-Terminus   	|    F42Q	|   V69A/Q74P/C125S    	|
|    N88D C-term        	|    C-Terminus   	|    N88D	|   C125A    	|
|    R38Q N-term        	|    N-Terminus   	|    R38Q	|   V69A/Q74P/C125S   	|
|    V91K C-term        	|    C-Terminus   	|    V91K	|   C125A   	|
|    WT C-term        	|    C-Terminus   	|    Wild-type	|   C125A    	|
|    WT N-term        	|    N-Terminus   	|    Wild-type	|   V69A/Q74P/C125S     	|

: **Modified IL-2 ligands and their respective mutations, and Fc conjugations.**

\cleardoublepage

### IL-2 variants' IL-2Rβ/γ~c~ affinities

Data Table SD1: **IL-2Rβ/γ~c~ binding affinities of mutant and modified cytokines.** Data from the BLI studies for each IL-2 mutein.

\cleardoublepage

![**Model without trafficking fails to capture IL-2/-15 dose response.** A) Model without trafficking fit to IL-2 and IL-15 pSTAT5 dose response data [@ring_mechanistic_2012]. This model was not fit to the surface IL-2Rβ measurements since no receptors were allowed to internalize from the cell surface ([@Fig:modelConstruct]B-D). B) Posterior distributions of analogous reverse reaction rates for IL-2 and IL-15 in no-trafficking model. C) Posterior distributions for receptor surface abundance in no-trafficking model. D) Posterior distribution for the pSTAT5 activity scaling constant in no-trafficking model. ](./Manuscript/Figures/figureS1.svg){#fig:supp1}

![**Geweke criterion scores for model fitting with and without trafficking.** Geweke criterion z-scores in all subplots were calculated using 20 intervals in the first 10% and last 50% of MCMC chain. Scores of |z| < 1 imply fitting convergence. A-B) IL-2/-15 with and without trafficking. C) IL-4/-7 with trafficking ([@Fig:supp1]). ](./Manuscript/Figures/figureS2.svg){#fig:supp2}

![**Receptor quantification and gating of PBMC-derived immune cell types.** A) Preliminary gating for single lyphocytes. B) Example staining for CD122 (red), the corresponding isotype control (blue), and unstained cells (black). C) Gating for live T helper and T regulatory cells during receptor quantification. D) Live cell NK cell gating. E) Live cell CD8+ T cell gating. F) Gating for fixed T helper and T regulatory cells during pSTAT5 quantification. G) Fixed CD8+ T cell and NK cell gating.](./Manuscript/gatingFigure.svg){#fig:gating}

![**Tucker factorization of predicted immune cell type responses.** A) Timepoint decomposition plot showing factorization component values against time after decomposing the tensor’s first dimension into 2 components. B) Decomposition plot along the second (cell) dimension after decomposing it to 2 components showing the ten cell type values along each component. C) Ligand decomposition plot along the tensor’s third dimension after decomposing it into 3 components. D–E) Slices of the Tucker core tensor corresponding to time component 1 (D) and 2 (E).](./Manuscript/Figures/figureS4.svg){#fig:supp4}

![**Full panel of predicted versus actual immune cell type responses.** Dots represent experimental measurements and shaded regions represent 10-90% confidence interval for model predictions. Time of pSTAT5 activity measurement is denoted by color. All cell populations were stimulated with either IL-2 (A-J) or IL-15 (K-T).](./Manuscript/Figures/figureS5.svg){#fig:supp5}

![**Cytokine affinity measurements to IL-2Rα.** Binding is quantified in relative units.](./Manuscript/CD25binding.pdf){#fig:supp6}

![**Full panel of predicted versus actual immune cell type responses to IL-2 muteins.** Dots represent experimental measurements and shaded regions represent 10-90% confidence interval for model predictions. Time of pSTAT5 activity measurement is denoted by color. Cell populations were stimulated with IL-2 muteins of varying IL-2Rα and IL-2Rβ/γ~c~ binding affinities.](./Manuscript/Figures/figureS7.svg){#fig:supp7 height=90%}
